Bioventix PLC (LON:BVXP – Get Free Report) insider Bruce Hiscock purchased 61 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were purchased at an average price of GBX 273 ($3.42) per share, with a total value of £166.53 ($208.76).
Bruce Hiscock also recently made the following trade(s):
- On Friday, November 22nd, Bruce Hiscock acquired 24 shares of Bioventix stock. The shares were bought at an average cost of GBX 3,822 ($47.91) per share, for a total transaction of £917.28 ($1,149.91).
- On Wednesday, October 30th, Bruce Hiscock acquired 300 shares of Bioventix stock. The stock was acquired at an average price of GBX 3,330 ($41.75) per share, with a total value of £9,990 ($12,523.51).
Bioventix Trading Down 0.8 %
BVXP traded down GBX 25.25 ($0.32) on Tuesday, hitting GBX 3,174.76 ($39.80). The company had a trading volume of 3,559 shares, compared to its average volume of 5,800. Bioventix PLC has a 1 year low of GBX 2,977 ($37.32) and a 1 year high of GBX 5,100 ($63.93). The company’s fifty day moving average price is GBX 3,634.44 and its 200 day moving average price is GBX 3,989.98. The firm has a market cap of £165.72 million, a P/E ratio of 1,947.70 and a beta of 0.35.
Bioventix Increases Dividend
About Bioventix
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.
See Also
- Five stocks we like better than Bioventix
- EV Stocks and How to Profit from Them
- 5 Reasons DraftKings Stock Looks Promising in the New Year
- ESG Stocks, What Investors Should Know
- Cybersecurity Stocks: 1 Immediate Buy and 1 Dip Opportunity
- Are Penny Stocks a Good Fit for Your Portfolio?
- The Next 2 AI Winners Have Triple-Digit Upside Potential
Receive News & Ratings for Bioventix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventix and related companies with MarketBeat.com's FREE daily email newsletter.